Management of the primary site in stage IV non-small cell lung cancer: SEER analysis.

52 Background: One of every three non-small cell lung cancer (NSCLC) patients is diagnosed with terminal stage IV disease. As systemic treatments have evolved, other tumor sites such as kidney have demonstrated benefits of aggressive management of the primary location and oligo-metastases. The purpose of this study is to use the SEER database to evaluate survival outcomes associated with surgery (S) and radiation treatment (RT) of the primary site in stage IV NSCLC. Methods: Eligible patient cases had lung coded as the primary location. The analysis was limited to histology of squamous cell carcinoma or adenocarcinoma, M1 staging, had recorded extent of surgery and status of radiation, were taken from years 1998-2013 and grouped from 1998-00, 01-05, 06-10, 11-2013 for temporal analysis. Kaplan-Meier was used to estimate median overall survival (MOS) and lung cancer specific survival (CSS). Results: There were 41150 patients meeting inclusion criteria with median follow up of 4 months limited by survival. ...